Skip to main content

BioMedNewsBreaks – MetAlert Inc. (MLRT) Approaching Inflection Point of Its Growth Curve

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, is launching a suite of wearable companion products to its innovative SmartSole shoe insole units. “The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The tech-designed insole may also be used by people at risk of kidnapping, such as children, government employees and select professionals. A next-generation shoe insole branded SmartSole plus incorporates biometric sensors paired with smart analytics to analyze the wearer’s movements for assessing overall health and wellness, and the company’s most recent product rollout – the in-home RoomMate system – uses 3D infrared motion-sensitive technology to allow caregivers to remotely monitor fall-prone loved ones in an unobtrusive manner,” a recent article reads. “MetAlert is approaching the inflection point of its growth curve by its ability to sell a multitude of products and services to a broader audience, which will result in greater revenue per user (‘RPU’),” MetAlert CEO Patrick Bertagna is quoted as saying.

To view the full article, visit https://ibn.fm/Gr9rl

About MetAlert Inc.

MetAlert is a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, supported through a proprietary IOT enterprise monitoring platform and intellectual property portfolio. The company offers global end-to-end solutions of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications, utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. MetAlert is known for its game-changing and award-winning patented GPS SmartSole – think Dr. Scholl’s meets LoJack, the world’s first visible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert’s subscription based business model is built around technology innovation and the company holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in over 40 countries and is a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.